Skip to main content

Can you take Revuforj with Tucatinib?

1 drug interaction and 11 additional warnings found for the following 2 drugs:

Add/remove drugs

Drug interactions

Major drug interactions

Major:

tucatinib revumenib

Applies to: tucatinib and Revuforj (revumenib)

Tucatinib may significantly increase the blood levels of revumenib. High levels of revumenib can increase the risk of an irregular heart rhythm that may be serious and potentially life-threatening.

You may be more susceptible if you have:

  • a heart condition called congenital long QT syndrome
  • other cardiac diseases
  • conduction abnormalities
  • electrolyte disturbances (for example, magnesium or potassium loss due to severe or prolonged diarrhea or vomiting)

Increased levels of revumenib may also increase the risk of developing a serious and potentially life-threatening condition called differentiation syndrome.

Symptoms of differentiation syndrome include:

  • fever
  • cough
  • shortness of breath
  • severe headache
  • confusion
  • dizziness or lightheadedness
  • rapid weight gain
  • swelling of the arms, legs, neck, groin, or underarm areas
  • decreased urination

You should seek immediate medical attention if you develop any of these symptoms and/or symptoms of QT prolongation such as sudden dizziness, lightheadedness, fainting, shortness of breath, or heart palpitations during treatment with revumenib.

The risk and/or severity of other side effects may also increase, including nausea, vomiting, diarrhea, fever or infections.

Talk to your doctor if you have any questions or concerns. Your doctor may be able to prescribe alternatives that do not interact, or you may need a dose adjustment or more frequent monitoring to safely use both medications.

It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.

Food/lifestyle interactions

Moderate food/lifestyle interactions

Moderate:

revumenib Food/Lifestyle

Applies to: Revuforj (revumenib)

High fat content meals may affect the absorption of revumenib. It is recommended that revumenib be taken while fasting or with a low fat meal (approximately 400 calories, with 25% of calories from fat).

Grapefruit juice may also increase the blood levels of revumenib which can increase the risk of an irregular heart rhythm that may be serious and potentially life-threatening.

You may be more susceptible if you have:

  • a heart condition called congenital long QT syndrome
  • other cardiac diseases
  • conduction abnormalities
  • electrolyte disturbances (for example, magnesium or potassium loss due to severe or prolonged diarrhea or vomiting)

Increased levels of revumenib may also increase the risk of developing a serious and potentially life-threatening condition called differentiation syndrome.

Symptoms of differentiation syndrome include:

  • fever
  • cough
  • shortness of breath
  • severe headache
  • confusion
  • dizziness
  • rapid weight gain
  • swelling
  • decreased urination

You should seek immediate medical attention if you develop any of these symptoms and/or symptoms of QT prolongation such as sudden dizziness, lightheadedness, fainting, shortness of breath, or heart palpitations during treatment with revumenib.

The risk and/or severity of other side effects may also increase, including nausea, vomiting, diarrhea, fever or infections. You may need additional monitoring if grapefruit or grapefruit juice are consumed during treatment with revumenib.

Talk to a healthcare provider if you have any questions or concerns. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.

Disease interactions

10 potential interactions Applies to: 8 conditions, including Heart Failure, Arrhythmia, Hypokalemia, Hyperkalemia, and Liver Disease.

Arrhythmia

Moderate:

Revuforj

The revumenib in Revuforj has a moderate potential interaction with Arrhythmia.

Revumenib can cause QTc interval prolongation. Correct electrolyte imbalances such as hypokalemia and hypomagnesemia, prior to treatment, and perform a baseline ECG. This drug should not be initiated in patients with QTcF greater than 450 msec. Monitor with ECG during treatment (once a week during the first 4 weeks and then monthly). More frequent ECG monitoring may be necessary in patients with congenital long QTc syndrome, congestive heart failure, electrolyte abnormalities, or those taking other medications that can prolong the QTc interval.

Heart Failure

Moderate:

Revuforj

The revumenib in Revuforj has a moderate potential interaction with Heart Failure.

Revumenib can cause QTc interval prolongation. Correct electrolyte imbalances such as hypokalemia and hypomagnesemia, prior to treatment, and perform a baseline ECG. This drug should not be initiated in patients with QTcF greater than 450 msec. Monitor with ECG during treatment (once a week during the first 4 weeks and then monthly). More frequent ECG monitoring may be necessary in patients with congenital long QTc syndrome, congestive heart failure, electrolyte abnormalities, or those taking other medications that can prolong the QTc interval.

Hyperkalemia

Moderate:

tucatinib

Tucatinib has a moderate potential interaction with Hyperkalemia.

Tucatinib contains 60.6 mg potassium per 300 mg dose. This should be taken into consideration especially in patients with hyperkalemia or impaired kidney function who are on a controlled potassium diet.

Hypokalemia

Moderate:

Revuforj

The revumenib in Revuforj has a moderate potential interaction with Hypokalemia.

Revumenib can cause QTc interval prolongation. Correct electrolyte imbalances such as hypokalemia and hypomagnesemia, prior to treatment, and perform a baseline ECG. This drug should not be initiated in patients with QTcF greater than 450 msec. Monitor with ECG during treatment (once a week during the first 4 weeks and then monthly). More frequent ECG monitoring may be necessary in patients with congenital long QTc syndrome, congestive heart failure, electrolyte abnormalities, or those taking other medications that can prolong the QTc interval.

Liver Disease

Moderate:

Revuforj

The revumenib in Revuforj has a moderate potential interaction with Liver Disease.

Revumenib has not been studied in patients with severe liver or renal impairment.

Moderate:

tucatinib

Tucatinib has a moderate potential interaction with Liver Disease.

Tucatinib is a hepatotoxic drug. Additionally, its exposure is increased in patients with severe hepatic impairment. This is the reason why the dosage must be reduced in these patients (Child-Pugh C). Consult the manufacturers prescribing information for details on dosage modification.

Long QT Syndrome

Moderate:

Revuforj

The revumenib in Revuforj has a moderate potential interaction with Long QT Syndrome.

Revumenib can cause QTc interval prolongation. Correct electrolyte imbalances such as hypokalemia and hypomagnesemia, prior to treatment, and perform a baseline ECG. This drug should not be initiated in patients with QTcF greater than 450 msec. Monitor with ECG during treatment (once a week during the first 4 weeks and then monthly). More frequent ECG monitoring may be necessary in patients with congenital long QTc syndrome, congestive heart failure, electrolyte abnormalities, or those taking other medications that can prolong the QTc interval.

Magnesium Imbalance

Moderate:

Revuforj

The revumenib in Revuforj has a moderate potential interaction with Magnesium Imbalance.

Revumenib can cause QTc interval prolongation. Correct electrolyte imbalances such as hypokalemia and hypomagnesemia, prior to treatment, and perform a baseline ECG. This drug should not be initiated in patients with QTcF greater than 450 msec. Monitor with ECG during treatment (once a week during the first 4 weeks and then monthly). More frequent ECG monitoring may be necessary in patients with congenital long QTc syndrome, congestive heart failure, electrolyte abnormalities, or those taking other medications that can prolong the QTc interval.

Renal Dysfunction

Moderate:

Revuforj

The revumenib in Revuforj has a moderate potential interaction with Renal Dysfunction.

Revumenib has not been studied in patients with severe liver or renal impairment.

Moderate:

tucatinib

Tucatinib has a moderate potential interaction with Renal Dysfunction.

Tucatinib contains 60.6 mg potassium per 300 mg dose. This should be taken into consideration especially in patients with hyperkalemia or impaired kidney function who are on a controlled potassium diet.

Report options

Loading...
QR code containing a link to this page

More resources

Revuforj

A total of 583 drugs are known to interact with Revuforj.

tucatinib

A total of 549 drugs are known to interact with tucatinib.

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer